Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: Wiley Periodicals, Inc on behalf of American Neurological Association Country of Publication: United States NLM ID: 101623278 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2328-9503 (Electronic) Linking ISSN: 23289503 NLM ISO Abbreviation: Ann Clin Transl Neurol Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: [Hoboken, NJ] : Wiley Periodicals, Inc on behalf of American Neurological Association, [2014]-
    • الموضوع:
    • نبذة مختصرة :
      Background: Gray matter (GM) pathology is closely associated with physical and cognitive impairment in persons with multiple sclerosis (PwMS). Similarly, serum neurofilament light chain (sNfL) levels are related to MS disease activity and progression.
      Objectives: To assess the cross-sectional and longitudinal associations between sNfL and MRI-derived lesion and brain volume outcomes in PwMS and age-matched healthy controls (HCs).
      Materials and Methods: Forty-seven HCs and 120 PwMS were followed over 5 years. All subjects underwent baseline and follow-up 3T MRI and sNfL examinations. Lesion volumes (LV) and global, tissue-specific and regional brain volumes were assessed. sNfL levels were analyzed using single molecule array (Simoa) assay and quantified in pg/mL. The associations between sNfL levels and MRI outcomes were investigated using regression analyses adjusted for age, sex, baseline disease modifying treatment (DMT) use and change in DMT over the follow-up. False discovery rate (FDR)-adjusted q-values <0.05 were considered significant.
      Results: In PwMS, baseline sNfL was associated with baseline T 1 -, T 2 - and gadolinium-LV (q = 0.002, q = 0.001 and q < 0.001, respectively), but not with their longitudinal changes. Higher baseline sNfL levels were associated with lower baseline deep GM (β = -0.257, q = 0.017), thalamus (β = -0.216, q = 0.0017), caudate (β = -0.263, q = 0.014) and hippocampus (β = -0.267, q = 0.015) volumes. Baseline sNfL was associated with longitudinal decline of deep GM (β = -0.386, q < 0.001), putamen (β = -0.395, q < 0.001), whole brain (β = -0.356, q = 0.002), thalamus (β = -0.272, q = 0.049), globus pallidus (β = -0.284, q = 0.017), and GM (β = -0.264, q = 0.042) volumes. No associations between sNfL and MRI-derived measures were seen in the HCs.
      Conclusion: Higher sNfL levels were associated with baseline LVs and greater development of GM atrophy in PwMS.
      (© 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.)
    • Comments:
      Comment in: Nat Rev Neurol. 2019 Oct;15(10):557. doi: 10.1038/s41582-019-0265-2. (PMID: 31506590)
      Erratum in: Ann Clin Transl Neurol. 2019 Dec;6(12):2607. doi: 10.1002/acn3.50955. (PMID: 31846573)
    • References:
      Neuroimage. 2012 Jan 2;59(1):331-9. (PMID: 21820063)
      Nat Rev Neurol. 2014 Aug;10(8):459-68. (PMID: 25002107)
      Lancet Neurol. 2014 Jan;13(1):113-26. (PMID: 24331797)
      Clin Chem Lab Med. 2016 Oct 1;54(10):1655-61. (PMID: 27071153)
      Ann Neurol. 2011 Feb;69(2):292-302. (PMID: 21387374)
      Brain. 2018 Aug 1;141(8):2382-2391. (PMID: 29860296)
      Lancet Neurol. 2015 Feb;14(2):183-93. (PMID: 25772897)
      Nat Rev Neurol. 2011 May 10;7(6):332-42. (PMID: 21556031)
      Neuroimage. 2011 Jun 1;56(3):907-22. (PMID: 21352927)
      Brain. 2016 Mar;139(Pt 3):807-15. (PMID: 26912645)
      Hum Brain Mapp. 2012 Dec;33(12):2802-14. (PMID: 21976406)
      Neurology. 2015 Jul 7;85(1):18-28. (PMID: 25888557)
      Lancet Neurol. 2012 Dec;11(12):1082-92. (PMID: 23153407)
      J Neuroimaging. 2017 Jan;27(1):107-113. (PMID: 27239049)
      Ann Neurol. 2018 Feb;83(2):223-234. (PMID: 29328531)
      Brain. 2013 Jun;136(Pt 6):1799-815. (PMID: 23687122)
      Ann Clin Transl Neurol. 2018 Oct 16;5(12):1478-1491. (PMID: 30564615)
      Neurology. 2019 Feb 12;92(7):e733-e741. (PMID: 30635483)
      Radiology. 2018 Nov;289(2):487-496. (PMID: 30015589)
      Ann Neurol. 2010 Oct;68(4):477-93. (PMID: 20976767)
      N Engl J Med. 1998 Jan 29;338(5):278-85. (PMID: 9445407)
      Neuroimage. 2018 Feb 15;167:438-452. (PMID: 29097315)
      J Neurol Sci. 2018 Oct 15;393:128-134. (PMID: 30165291)
      Neurology. 1983 Nov;33(11):1444-52. (PMID: 6685237)
      Brain. 2017 Mar 1;140(3):527-546. (PMID: 27794524)
      Brain. 2018 Jun 1;141(6):1665-1677. (PMID: 29741648)
      Radiology. 2013 Sep;268(3):831-41. (PMID: 23613615)
      Neurology. 2019 Mar 5;92(10):e1007-e1015. (PMID: 30737333)
      Expert Rev Neurother. 2016 Jul;16(7):777-93. (PMID: 27105209)
      AJNR Am J Neuroradiol. 2018 Aug;39(8):1480-1486. (PMID: 29976833)
      Nat Rev Neurol. 2018 Oct;14(10):577-589. (PMID: 30171200)
      Ann Neurol. 2008 Sep;64(3):255-65. (PMID: 18661561)
      Brain. 2016 Jan;139(Pt 1):115-26. (PMID: 26637488)
      J Neuroimaging. 2018 Sep;28(5):490-495. (PMID: 29856910)
      Brain. 2012 Oct;135(Pt 10):2938-51. (PMID: 23065787)
      Neuroimage. 2014 Apr 15;90:207-17. (PMID: 24333394)
      Eur J Neurol. 2019 Jan;26(1):87-e8. (PMID: 30103277)
      Ann Neurol. 2018 Feb;83(2):210-222. (PMID: 29331092)
      Nat Rev Neurol. 2019 Jun;15(6):329-342. (PMID: 31000816)
      Nat Rev Neurol. 2014 Apr;10(4):225-38. (PMID: 24638138)
      Mult Scler. 2017 Sep;23(10):1336-1345. (PMID: 27811339)
      Ann Neurol. 2017 Jun;81(6):857-870. (PMID: 28512753)
      Lancet Neurol. 2002 Aug;1(4):232-41. (PMID: 12849456)
    • Grant Information:
      International Novartis Pharma AG, Basel, Switzerland; 320030_160221 International Swiss National Research Foundation
    • الرقم المعرف:
      0 (Neurofilament Proteins)
    • الموضوع:
      Date Created: 20190823 Date Completed: 20200512 Latest Revision: 20200518
    • الموضوع:
      20250114
    • الرقم المعرف:
      PMC6764487
    • الرقم المعرف:
      10.1002/acn3.50872
    • الرقم المعرف:
      31437387